Ma Meng, Fei Xifeng, Jiang Dongyi, Chen Hanchun, Xie Xiangtong, Wang Zhimin, Huang Qiang
Department of Neurosurgery, Dushu Lake Hospital Affiliated to Soochow University, Suzhou, China.
Department of Neurosurgery, Suzhou Kowloon Hospital, Shanghai Jiaotong University School of Medicine, Suzhou, China.
Oncol Rev. 2024 Aug 12;18:1432131. doi: 10.3389/or.2024.1432131. eCollection 2024.
Glioma is the most prevalent primary malignant tumor of the central nervous system. While traditional treatment modalities such as surgical resection, radiotherapy, and chemotherapy have made significant advancements in glioma treatment, the prognosis for glioma patients remains often unsatisfactory. Ferroptosis, a novel form of programmed cell death, plays a crucial role in glioma and is considered to be the most functionally rich programmed cell death process. Histone deacetylases have emerged as a key focus in regulating ferroptosis in glioma. By inhibiting the activity of histone deacetylases, histone deacetylase inhibitors elevate acetylation levels of both histones and non-histone proteins, thereby influencing various cellular processes. Numerous studies have demonstrated that histone deacetylases are implicated in the development of glioma and hold promise for its treatment. This article provides an overview of research progress on the mechanism by which histone deacetylases contribute to ferroptosis in glioma.
神经胶质瘤是中枢神经系统最常见的原发性恶性肿瘤。虽然手术切除、放疗和化疗等传统治疗方式在神经胶质瘤治疗方面取得了显著进展,但神经胶质瘤患者的预后往往仍不尽人意。铁死亡是一种新型程序性细胞死亡形式,在神经胶质瘤中起关键作用,被认为是功能最丰富的程序性细胞死亡过程。组蛋白去乙酰化酶已成为调节神经胶质瘤中铁死亡的关键研究焦点。通过抑制组蛋白去乙酰化酶的活性,组蛋白去乙酰化酶抑制剂可提高组蛋白和非组蛋白的乙酰化水平,从而影响各种细胞过程。大量研究表明,组蛋白去乙酰化酶与神经胶质瘤的发生发展有关,并有望用于其治疗。本文综述了组蛋白去乙酰化酶在神经胶质瘤铁死亡中作用机制的研究进展。